VectorBuilder — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VectorBuilder has established itself as a leading global provider of gene delivery solutions, combining a sophisticated online design platform (VectorBee) with extensive wet-lab services. Its business model spans research tools, CRO services for library screening and cell line engineering, and CDMO capabilities for therapeutic-grade plasmid, viral vector, and LNP-RNA manufacturing. The company is positioned at the intersection of the rapidly growing gene therapy and CRISPR markets, leveraging its integrated platform to support clients from basic research to clinical development.

Gene TherapyCRISPR

Technology Platform

Integrated gene delivery platform combining the VectorBee online design software with wet-lab services for custom vector construction, viral packaging (Lentivirus, AAV, etc.), library screening, stable cell line engineering, and GMP manufacturing of plasmids, viral vectors, and RNA/LNPs.

Opportunities

The explosive growth in gene and cell therapy creates massive demand for reliable, scalable vector and virus production services.

VectorBuilder's expansion into GMP manufacturing (CDMO) and novel platforms like MiniVec plasmids and LNP-RNA positions it to capture high-value contracts from biotechs advancing into clinical stages.

Its global online platform allows it to efficiently acquire research clients who may become future development partners.

Risk Factors

The company faces intense competition from both large, established CDMOs and numerous niche service providers.

Scaling its GMP operations reliably and maintaining quality control for clinical materials presents significant execution risk.

Its growth is also tied to the overall health and funding environment of the gene therapy sector, which can be volatile.

Competitive Landscape

VectorBuilder competes in a fragmented but crowded market. In the research tools and CRO space, it competes with companies like GenScript, Thermo Fisher Scientific (GeneArt), and Sigma-Aldrich. In the CDMO segment for gene therapy, it faces larger, well-capitalized players like Lonza, Catalent, and Charles River Laboratories, as well as pure-play viral vector CDMOs. Its differentiation lies in its seamless online-to-wet-lab integration and broad service catalog.

More companies in Cell & Gene Therapy →More companies in Germany →